Surgery to lose weight changes the way our body perceives food.
“Obesity surgery helps obese people and diabetes to change the way the intestine perceives food and nutrients after the operation,” the researchers said Feb. 5 in the Journal of Cell Reports. The researchers found that after surgery, the gastrointestinal patterns of digestion and absorption changed, leading to higher levels of gastrointestinal hormones, especially the glucagon-1 (GLP-1) peptide, which in turn increased insulin production .
“For people who undergo gastric bypass surgery to treat obesity and who also have diabetes, after a reduction in body weight in surgery, diabetes melts quickly,” says lead author, Fiona Grippel, of the research laboratories of the University of Cambridge at Wellcome Trust. vexgen keto Institute of Metabolism. “But in patients with a lack of stomach cancer, they start to control their normal glucose and after the operation they end up having frequent hypoglycemia due to their low sugar levels.” The team wanted to know more about the mechanism that explains these adverse outcomes in glucose management.
Researchers have known for a long time that obesity surgery changed the way it digests the food it ingests and absorbs in the intestines. They also knew that cells that produce hormones in the intestine, such as the peptide GLP-1 and YY (PYY), increased. But they did not know the exact relationship between these facts. For this study, the team decided to focus on GLP-1 as it is an important hormone involved in the treatment of diabetes. At least half a dozen GLP-1 medications are available to control type 2 diabetes. “Our theory was that the high levels of GLP-1 produced after surgery are very important in improving blood glucose after surgery.” , says Gribble.
The team studied five people who underwent surgery to treat obesity in a hereditary form of stomach cancer. The participants received Exendin-9, a compound that inhibits the action of GLP-1, while taking oral glucose. The researchers found that the concentrations of insulin, the hormone responsible for lowering blood glucose levels, did not increase significantly when these individuals were administered Exendin-9 and did not experience episodes of high blood sugar. “We found that the hormonal blockade GLP-1 with Exendin-9 inhibited its effect on pancreatic beta cells that produce insulin,” says Gribble.